Share on StockTwits

Oncomed Pharmaceuticals (NASDAQ:OMED) EVP John A. Lewicki unloaded 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $23.86, for a total transaction of $95,440.00. Following the sale, the executive vice president now directly owns 20,000 shares of the company’s stock, valued at approximately $477,200. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Oncomed Pharmaceuticals (NASDAQ:OMED) traded down 0.92% during mid-day trading on Thursday, hitting $23.60. The stock had a trading volume of 58,090 shares. Oncomed Pharmaceuticals has a 1-year low of $12.07 and a 1-year high of $42.34. The stock has a 50-day moving average of $23.3 and a 200-day moving average of $29.03. The company’s market cap is $697.5 million.

Oncomed Pharmaceuticals (NASDAQ:OMED) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.13) by $0.34. Analysts expect that Oncomed Pharmaceuticals will post $-0.76 EPS for the current fiscal year.

A number of research firms have recently commented on OMED. Analysts at Mizuho reiterated a “buy” rating on shares of Oncomed Pharmaceuticals in a research note on Friday, June 13th. Separately, analysts at Zacks upgraded shares of Oncomed Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Tuesday, May 13th. They now have a $23.10 price target on the stock. Finally, analysts at Jefferies Group cut their price target on shares of Oncomed Pharmaceuticals from $50.00 to $48.00 in a research note on Friday, May 9th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $37.78.

OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.